Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Item

http://www.wikidata.org/entity/Q37193446

Q37193446

about

Regulation of glucose homeostasis by GLP-1 SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Adverse Effects of GLP-1 Receptor Agonists GLP-1 receptor agonists: a review of head-to-head clinical studies Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making Lixisenatide as add-on therapy to basal insulin Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes Update on the treatment of type 2 diabetes mellitus Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy Novel Agents for the Treatment of Type 2 Diabetes.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.The cardiovascular safety of incretin-based therapies: a review of the evidence.Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.

P2860

Q24563430-BB350062-77CD-4CD2-B5C6-73661D6E03F4 Q26746901-B5EE2965-E9D5-4B4A-9334-47811AE3E032 Q26749495-C8C97F46-7F96-460A-9507-4A33A9B99F39 Q26752699-9D13799A-BAE0-4C57-B9A5-36DF7AC81E01 Q26765155-347AC4F1-3389-47A7-9349-4173FFECAF07 Q26771823-D8A537F0-693D-4ED5-810C-B5B1CC0E4F88 Q26778608-A6338BBD-D4CE-49AC-A172-2102647D6C29 Q26801346-7DD24775-98AE-4162-8ED1-BBD4061ECAA6 Q26823768-24BF246B-E706-4AE8-B8E3-75A97C8FAD3D Q26992979-1FB7F090-F1A0-4FA7-B2E3-C94698F0E7FB Q27007547-F6A297E2-B297-4E7B-857B-578E717EF2EE Q27025423-3ADB112F-1744-4906-8318-B02AB4BFF9D4 Q28073342-F36123F3-F79E-4FEE-8AB4-48C347ED704D Q28077026-68F914F3-8272-4BA0-BB19-D264B4929D1A Q28546797-3E9FD3D6-A6B8-4769-ADA3-6F9E5B89D18A Q30249371-5041AE67-5AA1-4563-A616-F270EF7A9F02 Q31140045-4415B557-3A7E-4C29-932F-398497C2008E Q34543003-770FA5BB-74BA-4420-8F4A-89BAC8C551CC Q34547492-F179DE5A-FD05-4BDC-8F48-A77B93296F26 Q34726309-BEEB1BFD-BCB1-41F2-9DF8-935F2E069637 Q35061423-B28CFF70-17F7-445D-ACBB-2A8130B787C9 Q35192193-F83D4169-B4EE-4F43-B003-36FBD58D92E5 Q35667150-656B4183-384F-4F25-AF70-B4F13F2C4BA6 Q35910421-980A550B-368E-4834-B216-2C59F606167A Q36011993-10D75D9E-9306-4AD9-B64E-6FBBAB3F440A Q37340216-D45F7352-80EF-4DAC-BE33-36AAC3CD8B6A Q37340223-399A4564-0A2C-4ECE-80F1-4ED4E9EC2A9A Q37439806-D88D1841-82D9-41FC-A416-7A58208304D7 Q37633547-622FEE57-B8A5-470E-97BD-0F17097AB876 Q37639302-667352E9-BB47-42A1-AD2C-41F74CC5FD19 Q38134902-674267C4-6003-4EC4-AAD1-C7FCE991BB28 Q38174283-0DB0D29E-25E5-4DD8-B644-7292B64CAB67 Q38179267-99560FC5-34E3-4835-B10F-FB1A2C38EB68 Q38239573-D300201D-68F6-4055-8C4B-1B431A541F05 Q38243035-973185D9-AE4E-4353-B3F9-4BE1C3DC1A83 Q38266329-378F46D5-E4B7-4A43-9209-D38F8D6E1963 Q38270132-EE9CCCC6-701D-4348-B92B-F689437F988B Q38286444-514586E1-121A-4509-AE16-F9DD18C8EE93 Q38542098-F79B1D2B-E56D-4ECC-9CF6-F65A8D355E49 Q38597109-953FEC9F-F258-4850-BB33-E1F781D9848D

P2860

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Item

http://www.wikidata.org/entity/Q37193446

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs